<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940805-2-00139</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=21 g=1 f=3 --> ``Investigators submitting human gene transfer proposals for Recombinant DNA  <!-- PJG 0012 frnewline --> Advisory Committee review must include the Informed Consent document as  <!-- PJG 0012 frnewline --> approved by the local Institutional Review Boards. A separate Informed  <!-- PJG 0012 frnewline --> Consent document should be used for the gene transfer portion of a research  <!-- PJG 0012 frnewline --> project when gene transfer is used as an adjunct in the study of another  <!-- PJG 0012 frnewline --> technique, e.g., when a gene is used as a 'marker' or to enhance the power of  <!-- PJG 0012 frnewline --> immunotherapy for cancer.  <!-- PJG 0012 frnewline --> ``Because of the relative novelty of the procedures that are used, the potentially  <!-- PJG 0012 frnewline --> irreversible consequences of the procedures performed, and the fact that many  <!-- PJG 0012 frnewline --> of the potential risks remain undefined, the Informed Consent process should  <!-- PJG 0012 frnewline --> include the following specific information in addition to any requirements of the  <!-- PJG 0012 frnewline --> DHHS regulations for the Protection of Human Subjects (45 CFR 46). Indicate  <!-- PJG 0012 frnewline --> if each of the specified items appears in the Informed Consent document or, if  <!-- PJG 0012 frnewline --> not included in the Informed Consent document, how those items will be  <!-- PJG 0012 frnewline --> presented to potential subjects. Include an explanation if any of the following  <!-- PJG 0012 frnewline --> items are omitted from the consent process or the Informed Consent document.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=71 g=1 f=3 --> Appendix M&hyph;I&hyph;D&hyph;2&hyph;a. General Requirements of Human Subjects Research  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=3 --> Appendix M&hyph;I&hyph;D&hyph;2&hyph;a&hyph;(1). Description/purpose of the study.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG 0012 frnewline --> ``The subjects should be provided with a detailed explanation in non-technical  <!-- PJG 0012 frnewline --> language of the purpose of the study and the procedures associated with the  <!-- PJG 0012 frnewline --> conduct of the proposed study, including a description of the gene transfer  <!-- PJG 0012 frnewline --> component.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=3 --> Appendix M&hyph;I&hyph;D&hyph;2&hyph;a&hyph;(2). Alternatives.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> ``The Informed Consent document should indicate the availability of therapies  <!-- PJG 0012 frnewline --> and the possibility of other investigational interventions and approaches.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=3 --> Appendix M&hyph;I&hyph;D&hyph;2&hyph;a&hyph;(3). Voluntary participation.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> ``The subjects should be informed that participation in the study is voluntary and  <!-- PJG 0012 frnewline --> that failure to participate in the study or withdrawal of consent will not result in  <!-- PJG 0012 frnewline --> any penalty or loss of benefits to which the subjects are otherwise entitled.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=3 --> Appendix M&hyph;I&hyph;D&hyph;2&hyph;a&hyph;(4). Benefits.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> ``The subjects should be provided with an accurate description of the possible  <!-- PJG 0012 frnewline --> benefits, if any, of participating in the proposed study. For studies that are not  <!-- PJG 0012 frnewline --> reasonably expected to provide a therapeutic benefit to subjects, the Informed  <!-- PJG 0012 frnewline --> Consent document should clearly state that no direct clinical benefit to subjects  <!-- PJG 0012 frnewline --> is expected to occur as a result of participation in the study, although knowledge  <!-- PJG 0012 frnewline --> may be gained that may benefit others.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=3 --> Appendix M&hyph;I&hyph;D&hyph;2&hyph;a&hyph;(5). Possible risks, discomforts, and side effects.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> ``There should be clear itemization in the Informed Consent document of types  <!-- PJG 0012 frnewline --> of adverse experiences, their relative severity, and their expected frequencies.  <!-- PJG 0012 frnewline --> For consistency, the following definitions are suggested: side effects that are  <!-- PJG 0012 frnewline --> listed as mild should be ones which do not require a therapeutic intervention;  <!-- PJG 0012 frnewline --> moderate side effects require an intervention; and severe side effects are  <!-- PJG 0012 frnewline --> potentially fatal or life-threatening, disabling, or require prolonged  <!-- PJG 0012 frnewline --> hospitalization.  <!-- PJG 0012 frnewline --> ``If verbal descriptors (e.g., `rare,' `uncommon,' or `frequent') are used to express  <!-- PJG 0012 frnewline --> quantitative information regarding risk, these terms should be explained.  <!-- PJG 0012 frnewline --> ``The Informed Consent document should provide information regarding the  <!-- PJG 0012 frnewline --> approximate number of people who have previously received the genetic  <!-- PJG 0012 frnewline --> material under study. It is necessary to warn potential subjects that, for genetic  <!-- PJG 0012 frnewline --> materials previously used in relatively few or no humans, unforeseen risks are  <!-- PJG 0012 frnewline --> possible, including ones that could be severe.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            